High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.
NSCLC
DRUG: icotinib
Progression-free survival, 12 months
Overall survival, 20 months|Objective response rates, 12 weeks
This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.